Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.16B |
| 2 |
Bank of America
BAC
|
+$855M |
| 3 |
Comcast
CMCSA
|
+$620M |
| 4 |
Amazon
AMZN
|
+$505M |
| 5 |
Micron Technology
MU
|
+$486M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$441M |
| 2 |
Palo Alto Networks
PANW
|
+$300M |
| 3 |
Verizon
VZ
|
+$286M |
| 4 |
Fidelity National Information Services
FIS
|
+$285M |
| 5 |
Stanley Black & Decker
SWK
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Financials | 6.16% |
| 3 | Industrials | 5.09% |
| 4 | Consumer Discretionary | 4.89% |
| 5 | Healthcare | 4.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MZOR
4501
CALL
DELISTED
Mazor Robotics Ltd.
MZOR
| $996K | ﹤0.01% |
19,300
+3,400
| +21% | +$191K |
|
4502
PUT
Cullen/Frost Bankers
CFR
$10.6B
| $994K | ﹤0.01% |
10,500
+4,800
| +84% | +$462K |
|
4503
AC Immune
ACIU
$248M
| $993K | ﹤0.01% |
77,592
| – | – |
|
4504
CALL
Cheniere Energy
CQP
$33.4B
| $993K | ﹤0.01% |
+33,500
| New | +$943K |
|
4505
CALL
Vornado Realty Trust
VNO
$7.28B
| $993K | ﹤0.01% |
12,700
-3,600
| -22% | -$276K |
|
4506
Fresenius Medical Care
FMS
$12.7B
| $992K | ﹤0.01% |
18,873
-4,425
| -19% | -$220K |
|
|
SWCH
4507
DELISTED
Switch, Inc. Class A Common Stock
SWCH
| $992K | ﹤0.01% |
+54,566
| New | +$997K |
|
4508
Invesco FTSE RAFI Developed Markets ex-US Small-Mid ETF
PDN
$369M
| $991K | ﹤0.01% |
+28,802
| New | +$967K |
|
4509
CALL
Radian Group
RDN
$4.98B
| $991K | ﹤0.01% |
48,100
+10,000
| +26% | +$206K |
|
4510
AstraZeneca
AZN
$243B
| $990K | ﹤0.01% |
14,261
-298,307
| -95% | -$20.1M |
|
4511
ProShares Ultra VIX Short-Term Futures ETF
UVXY
$273M
| $990K | ﹤0.01% |
8
| – | – |
|
4512
CALL
Littelfuse
LFUS
$11.6B
| $989K | ﹤0.01% |
5,000
+1,400
| +39% | +$281K |
|
4513
State Street SPDR S&P Pharmaceuticals ETF
XPH
$518M
| $989K | ﹤0.01% |
22,731
-4,366
| -16% | -$186K |
|
|
GOLD
4514
DELISTED
Randgold Resources Ltd
GOLD
| $989K | ﹤0.01% |
10,000
-15,101
| -60% | -$1.44M |
|
4515
PUT
Plains GP Holdings
PAGP
$5.11B
| $988K | ﹤0.01% |
45,000
+4,600
| +11% | +$96.8K |
|
4516
CALL
Prospect Capital
PSEC
$1.15B
| $988K | ﹤0.01% |
146,600
+89,500
| +157% | +$584K |
|
4517
Spok Holdings
SPOK
$229M
| $988K | ﹤0.01% |
63,141
-18,912
| -23% | -$317K |
|
4518
Independent Bank Corp
IBCP
$850M
| $986K | ﹤0.01% |
44,117
+3,577
| +9% | +$80.5K |
|
|
JPXN
4519
iShares JPX-Nikkei 400 ETF
JPXN
$142M
| $986K | ﹤0.01% |
15,180
+5,920
| +64% | +$377K |
|
4520
CALL
AMN Healthcare
AMN
$1.34B
| $985K | ﹤0.01% |
20,000
+6,500
| +48% | +$296K |
|
4521
CALL
Copart
CPRT
$29.3B
| $985K | ﹤0.01% |
91,200
+36,800
| +68% | +$358K |
|
|
CVRR
4522
CALL
DELISTED
CVR Refining, LP
CVRR
| $985K | ﹤0.01% |
59,500
+6,800
| +13% | +$84K |
|
|
SODA
4523
CALL
DELISTED
SodaStream International Ltd
SODA
| $985K | ﹤0.01% |
14,000
-20,800
| -60% | -$1.38M |
|
4524
Vodafone
VOD
$37.9B
| $984K | ﹤0.01% |
30,856
-101,662
| -77% | -$3.05M |
|
|
ENDP
4525
CALL
DELISTED
Endo International plc
ENDP
| $984K | ﹤0.01% |
127,000
-5,200
| -4% | -$38.9K |
|
Similar funds
Ken Griffin's Q4 2017 Portfolio in Review
As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.
- Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
- Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
- Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
- Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
- Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
- Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.